Europese Unie - Nederlands - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemisch - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastische middelen - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tacrolimus 1-water 0,511 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 0,5 mg/stuk - capsule met verlengde afgifte, hard - allurarood ac (e129) ; allurarood ac aluminium lak (e 129) ; briljantblauw fcf (e 133) ; briljantblauw fcf aluminiumlak (e133) ; ethylcellulose (e 462) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; lecithine, soya (e 322) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; simeticon ; tartrazine (e 102) ; titaandioxide (e 171) ; zonnegeel fcf (e 110) ; zonnegeel fcf aluminiumlak (e 110) ; zwarte inkt - tacrolimus

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tacrolimus 1-water 1,022 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 1 mg/stuk - capsule met verlengde afgifte, hard - allurarood ac (e129) ; allurarood ac aluminium lak (e 129) ; briljantblauw fcf (e 133) ; briljantblauw fcf aluminiumlak (e133) ; ethylcellulose (e 462) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; lecithine, soya (e 322) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; simeticon ; titaandioxide (e 171) ; zonnegeel fcf (e 110) ; zonnegeel fcf aluminiumlak (e 110) ; zwarte inkt - tacrolimus

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tacrolimus 1-water 2,04 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 2 mg/stuk - capsule met verlengde afgifte, hard - allurarood ac (e129) ; allurarood ac aluminium lak (e 129) ; briljantblauw fcf (e 133) ; briljantblauw fcf aluminiumlak (e133) ; ethylcellulose (e 462) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; lecithine, soya (e 322) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; simeticon ; tartrazine (e 102) ; titaandioxide (e 171) ; zonnegeel fcf (e 110) ; zonnegeel fcf aluminiumlak (e 110) ; zwarte inkt - tacrolimus

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tacrolimus 1-water 3,06 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 3 mg/stuk - capsule met verlengde afgifte, hard - allurarood ac (e129) ; allurarood ac aluminium lak (e 129) ; briljantblauw fcf (e 133) ; briljantblauw fcf aluminiumlak (e133) ; ethylcellulose (e 462) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; lecithine, soya (e 322) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; simeticon ; titaandioxide (e 171) ; zonnegeel fcf (e 110) ; zonnegeel fcf aluminiumlak (e 110) ; zwarte inkt - tacrolimus

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tacrolimus 1-water 5,11 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 5 mg/stuk - capsule met verlengde afgifte, hard - allurarood ac (e129) ; allurarood ac aluminium lak (e 129) ; briljantblauw fcf (e 133) ; briljantblauw fcf aluminiumlak (e133) ; erythrosine (e 127) ; ethylcellulose (e 462) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; lecithine, soya (e 322) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; simeticon ; titaandioxide (e 171) ; zonnegeel fcf (e 110) ; zonnegeel fcf aluminiumlak (e 110) ; zwarte inkt - tacrolimus

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tacrolimus 1-water 0,51 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 0,5 mg/stuk - capsule met verlengde afgifte, hard - allurarood ac (e129) ; allurarood ac aluminium lak (e 129) ; briljantblauw fcf (e 133) ; briljantblauw fcf aluminiumlak (e133) ; ethylcellulose (e 462) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; lecithine, soya (e 322) ; magnesiumstearaat (e 470b) ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; simeticon ; tartrazine (e 102) ; titaandioxide (e 171) ; zonnegeel fcf (e 110) ; zonnegeel fcf aluminiumlak (e 110) ; zwarte inkt - tacrolimus